| Jul 9 |
BMO sees BMRN, LEGN, SLN as attractive M&A targets
|
| Jul 2 |
Johnson & Johnson's Cell Therapy Carvykti Shows Better Survival Rate In Pretreated Blood Cancer Patients
|
| Jul 2 |
J&J says Carvykti beat standard drugs in late-stage blood cancer trial
|
| Jul 2 |
Legend Biotech Announces Positive Overall Survival Results of Landmark Phase 3 CARTITUDE-4 Trial in Multiple Myeloma
|
| Jun 24 |
Does Legend Biotech (LEGN) Have a Long Runway for Growth?
|
| Jun 17 |
Legend Biotech's Cancer Drug, 'The Most Attractive Product,' Set For Growth: Analyst
|
| Jun 9 |
Novavax And Agios Pharmaceuticals Were Among The 10 Biggest Mid-Cap Gainers Last Week (June 1-June 7): Are These In Your Portfolio?
|
| Jun 3 |
J&J, Legend release promising results on Carvykti in earlier treatment line
|
| Jun 3 |
Legend Biotech Says Phase 2 Trial of Carvykti to Treat Multiple Myeloma Showed 'Deep, Durable' Responses
|
| Jun 3 |
Legend Biotech Shares Data on the Earliest Use to Date of CARVYKTI® in the Treatment of Multiple Myeloma and Important Subgroup Analyses at ASCO and EHA
|
